The Qualified Person for Batch Release: The Tightest Entry Gate in EU Pharma, and No Continuing Competence Requirement

No role in European pharmaceutical manufacturing is gated as tightly on the way in as the Qualified Person. The law specifies the degree, its minimum length, a named list of twelve subjects it must have covered, and the number of years of practical experience that must follow it, with the years varying by how long the degree took.

And once someone is in post, European law prescribes no continuing competence requirement for them at all. That inversion — the heaviest entry gate in the sector sitting above the lightest ongoing specification — is the thing worth understanding about this role.

The entry requirements

The qualifications sit in Article 49 of Directive 2001/83/EC, but Article 49 is applied by national competent authorities and their stated expectations are where the operative detail lives. The Danish Medicines Agency publishes an unusually explicit account, and it is used below as a worked example rather than as a pan-European statement — more on that distinction in a moment.

The degree. A diploma, certificate or other evidence of formal qualifications for a university degree of at least four years, in pharmacy, medicine, veterinary medicine, pharmaceutical chemistry and technology, chemistry or biology, with at least four years of the education falling within those disciplines. A three-and-a-half-year course is accepted where it is followed by at least one year of theoretical and practical training, including at least six months in a pharmacy open to the public.

The twelve subjects. The course must have covered applied physics; general and inorganic chemistry; organic chemistry; analytical chemistry; pharmaceutical chemistry, including analysis of medicinal products; general and applied medical biochemistry; physiology; microbiology; pharmacology; pharmaceutical technology; toxicology; and pharmacognosy. Some may be waived depending on the products the person will release, and an applicant with gaps must describe how the missing subjects were covered.

The experience. At least two years in manufacturing, quality assurance or quality control at a pharmaceutical company holding a manufacturing authorisation, equivalent to a full-time position. That falls to at least one year after a five-year degree, and at least half a year after a six-year degree. Product-specific experience is also required, particularly for sterile products, biological products and products for clinical trials, and it has to be documented in a training plan or a CV.

A caution on portability

The detail above is the Danish agency's published expectation. Member State interpretations of Article 49 differ, and the variation is well enough known to be the subject of its own comparative literature.

The practical consequence is that a QP assessment is not automatically portable. Someone accepted as a QP in one Member State should not assume the same evidence satisfies another authority, particularly on subject coverage and on whether a given year of experience counts. Anyone planning a cross-border appointment should take the receiving authority's published expectations directly.

What the role actually obliges

The duties come from Article 51, and the clearest operational summary is in Chapter 2 of Part 1 of the EU GMP guide, at point 2.6:

• Products made in the EU — the QP must ensure that each batch was manufactured and checked in accordance with the laws of that Member State and with the marketing authorisation.
• Products from third countries — the QP must ensure that each production batch underwent, in a Member State, a full qualitative analysis, a quantitative analysis of at least all the active substances, and any other checks necessary.
• Certification — the QP must certify in a register, or an equivalent document, as operations are carried out and before any release, that each batch meets Article 51.

There is a mutual recognition carve-out: batches tested in one Member State and marketed in another are exempt from repeat controls where they are accompanied by control reports signed by the QP.

The delegation rule, which is absolute

QP responsibilities may be delegated, but only to other Qualified Persons. That is the hard boundary, and it is what makes QP coverage a staffing problem rather than a workflow problem — there is no cascade to a senior technical person who is merely very experienced.

The QP must also be permanently and continuously at the disposal of the holder of the manufacturing authorisation, which is a separate requirement from being qualified and is often the one that constrains site operations.

How this plays out in practice is worth seeing concretely. Under Danish national rules, the authorised QP must make a release by signing the batch register before a batch can leave the manufacturer's custody, and countersigning is not sufficient for that purpose. Where delegated QPs release batches, the authorised QP must countersign all of their releases and randomly review them. Parts of the release process, such as reviewing batch documentation, may be delegated to other adequately qualified staff — but the batch register signature cannot be delegated at all.

So the reviewable work can be spread across a quality team; the act of certification cannot be spread anywhere.

The missing piece

Chapter 2 requires the QP to meet the Article 49 qualification requirements and to be permanently and continuously available. It does not describe specific training or continuing competence requirements for Qualified Persons.

That is a genuine absence rather than an oversight in the reading, and it puts the QP in a different category from almost every other named accountable role in regulated manufacturing and research. Compare:

• the FDA's Quality Management System Regulation now runs competence through ISO 13485 clause 6.2, which requires an effectiveness check proportionate to the risk of the work — see our guide to training and competence under the QMSR;
• ICH E6(R3) ties training to the activities actually delegated to a person;
• the Person Responsible for Regulatory Compliance under MDR Article 15 has defined qualifications attached to statutory duties;
• the Qualified Person for Pharmacovigilance carries its own qualification and availability expectations.

The QP has the most prescriptive entry standard of any of them and the least prescriptive ongoing one. It is the same structural pattern we described in the CORU context, where the Standards of Proficiency are explicitly entry-threshold standards and the ongoing duty has to be found somewhere else. The difference is that in the CORU case there is somewhere else to find it. For the QP, European law leaves the ongoing competence question to the manufacturer's own quality system.

Where the real risk sits

Product scope creep is the exposure, and it follows directly from how the entry gate is built.

The Article 49 assessment is product-aware: subject waivers depend on what the person will release, and product-specific experience is required for sterile, biological and clinical trial products. But that assessment happens once. Nothing in the Directive requires it to be revisited when a site's portfolio changes.

A QP assessed and appointed against a solid oral dose portfolio, whose site later takes on a sterile product or a biological, is certifying batches in a product class the entry assessment did not examine them for. The qualification remains valid. The competence question is live, and it is the manufacturer's quality system — not the Directive — that has to answer it. Sites running clinical trial material face the same question each time the Clinical Trials Regulation brings a new category of product through the door.

Our suggestions

Treat the QP's product scope as a controlled document rather than a historical fact. Record which product classes the appointment was assessed against, and trigger a documented competence review when the site adds a class, because nothing external will trigger it for you.

Build QP cover as a qualification problem, not a rota problem. Because delegation runs only to other QPs and the register signature cannot be delegated at all, single-QP sites have a continuity exposure that no amount of quality-team depth mitigates.

And if an appointment is cross-border, verify against the receiving authority's own published expectations before relying on it. Article 49 is one article; the assessments built on it are not interchangeable.